Xilio Therapeutics nabs $95m Series C
Xilio Therapeutics, a developer of immunotherapies for cancer patients, has raised $95 million in Series C financing.
Xilio Therapeutics, a developer of immunotherapies for cancer patients, has raised $95 million in Series C financing.
Copyright PEI Media
Not for publication, email or dissemination